Claims extracted
17
sentences that state something as happening or true
Uncertain
18%
3 of 17 hedged
("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
72/100
NBC News's corrections and
hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
2
Health
Same framing elsewhere
1
articles that frame the event the way this one does
The Food and Drug Administration said Monday that GLP-1 drugmakers must add a warning label about a rare eye condition that can cause sudden blindness.
asserted
that → say → blindness
The condition, called nonarteritic anterior ischemic optic neuropathy, or NAION, affects the optic nerve, which carries signals from the eye to the brain.
asserted
which → call → brain
When blood flow to the nerve is reduced or blocked, it can cause sudden vision loss.
asserted
it → reduce → loss
The condition is permanent with no known treatment.
asserted
condition → know → treatment
The FDA said “there is a potential increased risk of rare NAION” in people taking GLP-1 drugs.
asserted
FDA → say → drugs
The agency’s requirement applies to all GLP-1s, including Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound, as well as several older GLP-1 diabetes medications.
asserted
requirement → apply → Ozempic
Spokespeople for both Novo Nordisk and Eli Lilly said patient safety is their top priority.
asserted
safety → say → Nordisk
Previous research has found that GLP-1 use may increase the risk of NAION, and Lilly has said it was aware of studies on the potential link.
uncertain
it → find → link
The FDA said it began looking into a possible link after a 2024 study published in JAMA Ophthalmology that found diabetes patients prescribed semaglutide were four times as likely to develop NAION as those not prescribed the drug.
asserted
patients → say → drug
The agency said it reviewed reports of side effects submitted to its adverse event monitoring system and analyzed data from multiple clinical trials.
asserted
it → say → trials
Cases of NAION have been reported for all currently marketed GLP-1 drugs, the FDA found.
asserted
FDA → report → drugs
However, FDA scientists were not able to identify a mechanism for how the drugs could increase the risk of the eye condition.
uncertain
drugs → identify → condition
Risk factors for NAION can overlap with conditions seen in people taking GLP-1 drugs, including Type 2 diabetes, sleep apnea and hypertension.
asserted
factors → overlap → diabetes
NAION is the second most common optic nerve disease in the U.S., occurring in up to 10 out of 100,000 people over age 50, according to the American Academy of Ophthalmology.
uncertain
NAION → occur → Ophthalmology
“Patients and caregivers should be aware of a potential increased risk of NAION, a rare condition that can result in acute, painless, decreased vision in one eye, including permanent vision loss,” with GLP-1 use, the FDA said in the release.
asserted
FDA → increase → release
The drug labels from Novo Nordisk and Lilly also carry other warnings, including for pancreatitis, gallbladder problems and kidney injury.
asserted
labels → carry → pancreatitis
The labels also carry a black box warning — the FDA’s strongest safety warning — about a possible risk of thyroid tumors.
asserted
labels → carry → tumors
The Aporia
